BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA's Approval for Patients with Hepatocellular Carcinoma Prior Treated with Sorafenib
Shots:
- The approval is based on P-I/II CheckMate -040 study assessing Opdivo (1 mg/kg- IV) + Yervoy (3 mg/kg- IV) q3w for four doses- followed by Opdivo (240mg- q2w) in 49 patients with HCC prior treated with sorafenib
- The P-I/II CheckMate -040 study results: @28mos. follow-up- 33% of patients respond to combination therapy; CR (8%); PR (24%); DOR (4.6 to 30.5+ mos.) with 88% lasting at least 6mos.- 56% at least 12mos. and 31% @24 mos.
- Opdivo + Yervoy is the first and only dual immunotherapy approved in this setting and has received FDA’s BT & PR designation for the same indication
Click here to read full press release/ article
Ref: BMS | Image: BMS
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com